Trial Profile
Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- 19 Nov 2021 Status changed from recruiting to discontinued.
- 10 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 10 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.